COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥57 | ¥52 | ¥46 | ¥37 |
| Short-Term Investments | ¥0 | ¥0 | ¥0 | ¥0 |
| Receivables | ¥12 | ¥12 | ¥10 | ¥9 |
| Inventory | ¥92 | ¥86 | ¥77 | ¥66 |
| Other Curr. Assets | ¥1 | ¥1 | ¥1 | ¥1 |
| Total Curr. Assets | ¥166 | ¥154 | ¥137 | ¥115 |
| Property Plant & Equip (Net) | ¥331 | ¥296 | ¥275 | ¥239 |
| Goodwill | ¥0 | ¥0 | ¥0 | ¥0 |
| Intangibles | ¥0 | ¥0 | ¥1 | ¥0 |
| Long-Term Investments | ¥4 | ¥4 | ¥4 | ¥4 |
| Tax Assets | ¥3 | ¥3 | ¥2 | ¥2 |
| Other NC Assets | ¥20 | ¥19 | ¥2 | ¥2 |
| Total NC Assets | ¥359 | ¥322 | ¥284 | ¥248 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥525 | ¥477 | ¥421 | ¥363 |
| Liabilities | – | – | – | – |
| Payables | ¥177 | ¥180 | ¥162 | ¥139 |
| Short-Term Debt | ¥6 | ¥5 | ¥3 | ¥1 |
| Tax Payable | ¥0 | ¥6 | ¥6 | ¥5 |
| Deferred Revenue | ¥0 | ¥1 | ¥1 | ¥0 |
| Other Curr. Liab. | ¥27 | ¥13 | ¥13 | ¥8 |
| Total Curr. Liab. | ¥221 | ¥213 | ¥192 | ¥162 |
| LT Debt | ¥37 | ¥23 | ¥10 | ¥3 |
| Deferred Rev, NC | ¥0 | ¥4 | -¥0 | -¥0 |
| Deferred Tax Liab, NC | ¥0 | ¥0 | ¥0 | ¥0 |
| Other NC Liab. | ¥5 | ¥4 | ¥4 | ¥4 |
| Total NC Liab. | ¥47 | ¥32 | ¥18 | ¥10 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥7 | ¥6 | ¥5 | ¥5 |
| Total Liabilities | ¥267 | ¥245 | ¥210 | ¥173 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥4 | ¥4 | ¥4 | ¥4 |
| Retained Earnings | ¥248 | ¥222 | ¥202 | ¥182 |
| AOCI | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Equity | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Equity | ¥257 | ¥231 | ¥211 | ¥191 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥525 | ¥477 | ¥421 | ¥363 |
| Net Debt | -¥14 | -¥24 | -¥33 | -¥33 |